Gene expression profiling of tamoxifen-associated uterine cancers: Evidence for two molecular classes of endometrial carcinoma

Gynecologic Oncology

Volumn 92, Issue 2, 2004, Pages 719-725

  Ferguson, Sarah E ^a   Olshen, Adam B ^a   Viale, Agnès ^a   Awtrey, Christopher S ^a   Barakat, Richard R ^a   Boyd, Jeff ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Endometrial carcinoma; Gene expression profile; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GENETICS; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UTERUS CANCER;

EID: 0842267344     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.10.038     Document Type: Article

References (19)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J. Clin. 53:1999;5-26.
2. Kurman R.J., Zaino R.J., Norris H.J. Endometrial carcinoma. Kurman R.J. Blaustein's pathology of the female genital tract. third ed. 1994;439-486 Springer, New York.
3. Boyd J., Hamilton T.C., Berchuck A. Oncogenes and tumor-suppressor genes. Hoskins W.J., Perez C.A., Young R.C. Principles and practice of gynecologic oncology. third ed. 2000;103-128 Lippincott Williams and Wilkins, Philadelphia.
4. Parazzini F., La Vecchia C., Bocciolone L., Franceschi S. The epidemiology of endometrial cancer. Gynecol. Oncol. 41:1991;1-16.
5. Kaaks R., Lukanova A., Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 11:2002;1531-1543.
6. Jordan V.C. The secrets of selective estrogen receptor modulation: cell-specific coregulation. Cancer Cells. 1:2002;215-217.
7. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:1994;527-537.
8. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M.et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1998;1371-1388.
9. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Lancet. 356:2000;881-887.
10. Barakat R.R., Wong G., Curtin J.P., Vlamis V., Hoskins W.J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol. Oncol. 55:1994;164-168.
11. Preston-Martin S., Pike M.C., Ross R.K., Jones P.A., Henderson B.E. Increased cell division as a cause of human cancer. Cancer Res. 50:1990;7415-7421.
12. Yager J.D. Endogenous estrogens as carcinogens through metabolic activation. J. Natl. Cancer Inst. Monogr. 27:2000;67-73.
13. Barakat R.R., Grigsby P.W., Sabbatini P., Zaino R.J. Corpus: epithelial tumors. Hoskins W.J., Perez C.A., Young R.C. Principles and practice of gynecologic oncology. third ed. 2000;919-960 Lippincott Williams and Wilkins, Philadelphia.
14. Rickman D.S., Bobek M.P., Misek D.E., Kuick R., Blaivas M., Kurnit D.M. et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 61:2001;6885-6891.
15. Jazaeri A.A., Lu K., Schmandt R., Harris C.P., Rao P.H., Sotiriou C.et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol. Carcinog. 36:2003;53-59.
16. Kuttler F., Valnet-Rabier M.B., Angonin R., Ferrand C., Deconinck E., Mougin C.et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia. 16:2002;726-735.
17. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.et al. The sequence of the human genome. Science. 291:2001;1304-1351.
18. Schneider C., King R.M., Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell. 54:1988;787-793.
19. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115:2002;3719-3727.